Evidence map›Paper›PMID 36328438›Full record

Trial reportHuman vaccines & immunotherapeutics2022

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies.

Xiaoqiang Liu, Juliana Park, Shengli Xia, Bin Liang, Shuangmin Yang, Yanxia Wang, Olga Syrkina, Nathalie Lavis, Shuzhen Liu, Chenyan Zhao and 5 more

2 registry-linked trialsOpen access · goldAbstract readEquivalence TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03430089 phase1completednot on this map

Safety of a Single Dose (Participants Aged 9 Years and Older) or Two Doses Given 28 Days Apart (Participants Aged 6 Months to 8 Years) of the Shenzhen Quadrivalent Influenza Vaccine (Split Virion), Inactivated

TypeinterventionalSponsorSanofi Pasteur, a Sanofi CompanyRan2019 to 2019Enrolled101ConditionsInfluenza, FluArmsShz QIV 0.25 mL, 2 doses, Shz QIV 0.5 mL, 2 doses, Shz QIV 0.5 mL, single dose
NCT04210349 phase3completednot on this map

Immunogenicity and Safety of the Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

TypeinterventionalSponsorSanofi Pasteur, a Sanofi CompanyRan2020 to 2020Enrolled7,106ConditionsInfluenzaArmsQuadrivalent Influenza Vaccine, Trivalent Influenza Vaccine 1 SP Shz TIV1, Trivalent Influenza Vaccine 2 SP Shz TIV2
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

Xiaoqiang LiuVaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan, China.
Juliana ParkGlobal Clinical Development, Sanofi, Sydney, Australia.
Shengli XiaInstitute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan, China.
Bin LiangChina Medical, Sanofi, Beijing, China.
Shuangmin YangVaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan, China.
Yanxia WangInstitute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan, China.
Olga SyrkinaGlobal Pharmacovigilance, Sanofi, Swiftwater, Pennsylvania, USA.
Nathalie LavisGlobal Medical, Sanofi, Lyon, France.
Shuzhen LiuDepartment of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
Chenyan ZhaoDepartment of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
Jian DingChina Medical, Sanofi, Beijing, China.
Jieqiong HuGlobal Clinical Development, Sanofi, Sydney, Australia.
Sandrine I SamsonGlobal Medical, Sanofi, Lyon, France.
Iris A de BruijnGlobal Clinical Development, Sanofi, Marcy l'Etoile, France.
FSQ01 and FSQ02 Study Groups
Sanofi (France) · FRHenan Provincial Center for Disease Control and Prevention · CNNational Institutes for Food and Drug Control · CNSanofi (Australia) · AUSanofi (China) · CNYunnan Center for Disease Control And Prevention · CNSanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WHO UNIVERSAL TRIAL NUMBERS (UTNS): U1111-1174-4615 and U1111-1174-4698. CLINICALTRIALS.GOV: NCT04210349 and NCT03430089.

Indexed as

Influenza, HumanInfluenza VaccinesAntibodies, ViralHemagglutination Inhibition TestsHumansImmunogenicity, VaccineInfluenza B virusVaccines, CombinedVaccines, InactivatedAntibodies, ViralInfluenza VaccinesVaccines, CombinedVaccines, InactivatedChinaelderlyimmunogenicityinactivated influenza vaccinepediatricquadrivalentsafety

Identifiers

PMID36328438
PMCPMC9746500
OpenAlexW4308072559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.